IVDT Insight

Ventana Licenses Gen-Probe IP for Measuring ERG Protein in Prostate Cancer Patients

Ventana Medical Systems Inc., a member of the Roche Group, announced that it has co-exclusively sub-licensed certain patents and patent applications from Gen-Probe Inc. for the worldwide IVD rights for measuring ERG protein expression through immunohistochemistry (IHC) in prostate tissue. The license complements the existing Ventana sublicense for in situ hybridization (ISH) rights for measuring ETS gene rearrangements, including ERG gene rearrangements in tissue.
Ventana believes that the emerging biomarker will enable novel clinical assays and personalized healthcare for prostate cancer.
“We believe ERG testing by IHC and ISH will play an important role in novel diagnostic, prognostic, and predictive tests for prostate cancer,” says Mara G. Aspinall, President of Ventana Medical Systems. “This license gives us a unique position for...

read more >>
May 21st, 2012
0
Agilent Technologies to Acquire Dako for $2.2 Billion

read more >>
May 18th, 2012
0
FDA Advisory Committee Issues Unanimous Recommendation for OraQuick In-Home HIV Test

OraSure Technologies Inc. yesterday announced that FDA's Blood Products Advisory Committee (BPAC) provided a unanimous positive recommendation for the company's OraQuick In-Home HIV Test. The BPAC provides advice to the FDA on issues related to the safety and effectiveness of biological products and medical devices seeking FDA approval.

The BPAC voted on two questions posed by FDA:

  • Do the projected benefits of the test outweigh the potential risks of false positive and false negative test results? The committee voted 17-0 in the affirmative to that question.
  • Do the available data provide reasonable assurance that the test is safe and effective for its intended use? The committee voted 17-0 in the affirmative to that question.

In addition to reviewing the company's clinical data and performance, the...

read more >>
May 16th, 2012
0
FDA Expands Use for FilmArray Respiratory Panel

This week FDA expanded the use for the FilmArray Respiratory Panel, the first test that can simultaneously detect both viral and bacterial causes of respiratory infection from a single sample.
The expanded use of the panel adds the bacteria Bordetella pertussis, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. The FilmArray Respiratory Panel is the first FDA-cleared molecular diagnostic test able to identify the three bacteria.
Bordetella pertussis is the cause of pertussis, or whooping cough, a serious disease in very young children. Mycoplasma pneumoniae is a common cause of respiratory infection and community-acquired pneumonia, sometimes resulting in large outbreaks, especially in children and young adults. Chlamydophila pneumoniae is a cause of community-acquired pneumonia that can be more serious in...

read more >>
May 16th, 2012
0
Buoyant Growth Predicted for IVDs in BRICs

Looking for more than modest growth for your IVD product portfolio? Focus on the BRICs, says a new report from GlobalData. Brazil, Russia, India and China (BRIC) represent growth opportunities for the diagnostic testing industry, as population growth and unhealthy lifestyles in these emerging economies expand the patient population.

The report, titled In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018, predicts that new technologies, a shift towards point of care (POC) testing and cost containment will drive growth over the coming years. "The ever increasing patient pool, improving healthcare...

read more >>
May 10th, 2012
0
Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Sequencing Software

454 Life Sciences, a Roche company, and SoftGenetics announced today that the two firms have entered into a copromotion agreement designed to provide users of 454 Sequencing Systems the range of next-generation sequencing data analysis options provided by SoftGenetics’ NextGENe software.

Roche describes the software as being “a free-standing, biologist-friendly software multi-package that is fully compatible with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling, and more.”

The software package provides additional options for users of 454 sequencing systems, in addition to the GS Data Analysis Software suite provided with the platforms.
 
 “This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace,”...
read more >>
May 9th, 2012
0
Molecular Diagnostics Is Star Performer of Global IVD Market Projected to Show Overall Modest Growth

Valued at $44 billion in 2011, the global IVD market is expected to experience modest growth through 2016, according to a report published by reportlinker.com. The United States represents approximately half of the total market for IVD equipment, notes In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) - Global Trends & Forecasts to 2016.

Various segments of the IVD market are analysed in the 394-...

read more >>
May 9th, 2012
0
Novel Compound Could Potentially Disrupt Amyloid Formation in Alzheimer's Patients

UC Davis researchers have found novel compounds that disrupt the formation of amyloid, the clumps of protein in the brains of people with Alzheimer’s disease believed to be important in causing the disease’s characteristic mental decline. The so-called “spin-labeled fluorene compounds” are an important new target for researchers and physicians focused on diagnosing, treating and studying the disease.
The study, published recently in the online journal PLoS ONE, is called “The influence of spin-labeled fluorene compounds on the assembly and toxicity of the Aβ peptide.”
“We have found these small molecules to have significant beneficial effects on cultured neurons, from protecting against toxic compounds that form...

read more >>
May 9th, 2012
0
New to U.S. Retail Shelves: Blood Glucose Monitor that Connects to iPhone (And an App To Match)

Sanofi's iPhone-compatible blood glucose monitor and app

read more >>
May 7th, 2012
0
UCLA Prof Can Turn Your Smartphone Into a Rapid Dx Test Reader

Rapid diagnostic test reader developed at UCLA
Smartphone with RDT reader developed by researchers from the UCLA Henry Samueli School of Engineering and Applied Science and the California NanoSystems Institue at UCLA. Image: UCLA

Aydogan Ozcan, a UCLA professor of electrical engineering and bioengineering, and his colleagues from the UCLA Henry Samueli School of Engineering and Applied Science and the California NanoSystems Institute at UCLA have developed a compact and cost-effective rapid-diagnostic-test-reading device that works in tandem with "smart" mobile phones, such as iPhones. “What we have created is...
read more >>
May 4th, 2012
0